On October 21, the Utah Department of Health and Human Services (DHHS) released a bulletin to Utah medical cannabis patients regarding the detection of synthetic cannabinoids in state-sponsored medical cannabis sales. The DHHS now requires that if a medical cannabis product contains a synthetic or derivative ingredient, the label will include the following statement: “This product contains a derivative and/or synthetic cannabinoid.” But some advocates say it isn’t enough.  Read the article here.